Bio Rad Laboratories (BIO) Following ddPCR Expansion Narrative Looks Fully Valued

Bio-Rad Laboratories (BIO) has drawn investor attention after recent share moves, with the stock up 0.8% on the day and 6.5% over the past week, despite a decline over the past month.

See our latest analysis for Bio-Rad Laboratories.

Set against a 1 year total shareholder return of 23.3% but a 5 year total shareholder return that is down 54.9%, Bio-Rad Laboratories’ recent 6.5% 7 day share price gain after a weaker 30 day share price return suggests short term momentum is improving, while longer term holders still sit on sizeable drawdowns.

If you want to see what else is moving in related areas of the market, this could be a useful moment to scan for healthcare focused AI opportunities via our 39 healthcare AI stocks

With Bio-Rad Laboratories trading near analyst targets and at an indicated intrinsic premium rather than a discount, the key question now is whether the recent momentum signals a mispriced entry point or a market that is already banking on future growth.

Most Popular Narrative: 3% Overvalued

At a last close of $300.79 versus a narrative fair value of $293, Bio-Rad Laboratories is priced slightly above that widely followed estimate, which rests on relatively modest growth, margin and valuation assumptions.

Recent launch and expansion of the QX Continuum and QX700 Series ddPCR platforms, alongside the acquisition of Stilla Technologies, positions Bio-Rad to accelerate its share capture as demand grows for advanced molecular diagnostics and precision medicine tools; this is expected to drive ddPCR revenue growth and improve margins through higher consumable pull-through and broader assay adoption.

Read the complete narrative.

Curious what kind of revenue mix, margin rebuild and earnings multiple are baked into that fair value number? The narrative leans on gradual growth, fatter margins and a richer future P/E, all tied to diagnostics and consumables momentum. The full breakdown shows exactly how those moving parts are expected to add up.

Result: Fair Value of $293 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Bio-Rad Laboratories still faces pressure from softer instrument demand and Clinical Diagnostics headwinds in markets like China. These factors could challenge the current fair value narrative.

Find out about the key risks to this Bio-Rad Laboratories narrative.

Another View on Bio-Rad Laboratories’ Valuation

While the fair value narrative pegs Bio-Rad Laboratories at $293 and labels the stock as slightly overvalued, the current P/E of 47.7x tells a sharper story. It sits well below peers at 83.8x, but far above a fair ratio of 16.7x, which points to meaningful valuation risk if sentiment cools.

Put simply, the stock trades richer than what the fair ratio suggests the market could move toward, even if it still looks cheaper than some direct peers. For investors, the key question is whether that premium reflects durable strengths or expectations that may be hard to meet over time.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment around Bio-Rad Laboratories looking mixed, this is a moment to move quickly, assess the data yourself and decide where you stand. To help balance the upside potential against the areas of concern, start by weighing 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Bio-Rad Laboratories?

If you find Bio-Rad Laboratories interesting but do not want to rely on a single stock, broaden your watchlist using focused screeners that highlight different strengths.

• Target dependable compounding potential by checking companies with strong cash flows and attractive valuations through our 44 high quality undervalued stocks
• Prioritize resilience by reviewing stocks that pair financial strength with lower risk profiles using the 71 resilient stocks with low risk scores
• Spot future standouts early by scanning a screener containing 19 high quality undiscovered gems before the wider market pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com